Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com -- Shares of Inventiva Sa (Nasdaq: IVA) climbed 5.4% as the company announced the completion of patient enrollment for its NATiV3 Phase 3 clinical trial, which exceeds its initial patient target. The clinical-stage biopharmaceutical company, which specializes in oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases, reported the randomization of the last patient in the main cohort of the trial.
The company’s CEO, Frederic Cren, expressed that this achievement marks a significant milestone for Inventiva’s leading drug candidate, lanifibranor, and its development. With topline results anticipated in the second half of 2026, there is potential for lanifibranor to become an approved oral therapy for MASH treatment. Prof. Arun Sanyal, co-principal investigator of NATiV3, also conveyed strong confidence in lanifibranor’s potential, highlighting the significant unmet medical need for MASH patients and the drug’s unique mechanism of action.
Inventiva’s stock movement reflects investor optimism following the update on the NATiV3 trial, which also aligns with the conditions for the second tranche of approximately €116 million of structured financing announced in October 2024. The successful enrollment supports the satisfaction of specific conditions related to the funding, although the company notes that there is no guarantee that all conditions for the financing will be met.
Stifel analyst Samimy Annabel has reiterated a Buy stock rating and a $17.00 price target on Inventiva shares. "With multiple positive safety reviews from an independent DMC and a blinded interim review (Sep. 2024) indicating improving trends on multiple key biomarkers, we believe NATiV3 has a high likelihood to replicate the positive Ph.2b NATIVE trial—topline results are expected in 2H26," said Annabel.
Investors are now eyeing the next major milestone for Inventiva, which is the expected release of topline results from the NATiV3 trial in the latter half of 2026. The company’s progress and the analysts’ positive outlook contribute to the current upward trend in stock price.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.